奎寧定鹽酸鹽
奎寧定鹽酸鹽 性质
| 熔点 | 258-259 C |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：100mg/mL（263.93mM）；水：2.5 mg/mL（6.60 mM） |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChIKey | SGVZDMWHXVXUBY-KAIFKDDSSA-N |
| SMILES | O.Cl.[H][C@@]1(C[C@@H]2CC[N@H]1C[C@@H]2C=C)[C@@H](O)c3ccnc4ccc(OC)cc34 |
奎寧定鹽酸鹽 用途与合成方法
IC50: 19.9 μM (K + channel)
Quinidine hydrochloride monohydrate blocks WT mSlo3 (K Ca 5.1) channels with an IC 50 of 19.9±1.41 μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC 50 of 2.42±0.60 μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC 50 of 38.4±6.77 μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence.
Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side.
安全信息
| 危险品标志 | Xn,Xi |
|---|---|
| 危险类别码 | 20/21/22-36/37/38 |
| 安全说明 | 36-26 |
| 危险品运输编号 | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经皮 急性毒性 类别4 吸入 急性毒性 类别4 经口 |
奎寧定鹽酸鹽 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-B1302 | 奎寧定鹽酸鹽 | 6151-40-2 | 100mg | 500 |
| 2025-12-22 | HY-B1302 | 奎寧定鹽酸鹽 | 6151-40-2 | 10mM * 1mLin DMSO | 550 |
